CClinicalTrials.gg
CompletedNCT06554262Updated Aug 15, 2024

Visceral Fat and Cardiometabolic Risk

An observational study in Cardiometabolic Risk, Visceral Fat and Cohort Study, sponsored by Capital Medical University. Completed. Open to participants aged 6 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-15.

Sponsored by Capital Medical University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
18,938
Ages
6 Years to 18 Years
Sex
All
01

Study summary

The present study showed that the 75th percentile of visceral fat area in boys and girls is the optimal cutoff for screening cardiometabolic risk and its clustering, but the 80th percentile is the optimal cutoff for hyperglycemia screening in girls. The investigators proposed simplified cutoffs of 37.19 cm2 and 31.09 cm2 aged 6 to 8 years, 56.76 cm2 and 39.51 cm2 aged 9 to 11 years, 57.03 cm2 and 38.33 cm2 aged 12 to 15 years, and 58.32 cm2 and 53.91 cm2 aged 16 to 18 years for boys and girls, respectively. Both the optimal and simplified methods were verified in a 2-year longitudinal cohort. An improved understanding of the importance of visceral fat to cardiometabolic risk and its clustering in children may yield insight into the risks associated with child obesity and the initial phases of cardiovascular disease development, especially in normal-weight boys.

02

Conditions studied

  • Cardiometabolic Risk
  • Visceral Fat
  • Cohort Study
03

In context

Lead sponsor

Capital Medical University is the lead sponsor of 283 studies on the registry; 92 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A total of 8133 participants (mean age =11.8 years, SD =3.3 years) from the China Child and Adolescent Cardiovascular Health completed the visceral fat area assessment by dual-energy X-ray absorptiometry, and 10805 participants from the school-based cardiovascular and bone health program (mean age =11.0 years, SD =3.3 years).

Inclusion criteria

Healthy children and adolescents aged 6-18 years

Exclusion criteria

Exclusion Criteria:

Heart disease Kidney disease Thyroid disease Individuals who take hormone medication Missing data for anthropometry

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
18,938 participants (actual)
Patient registry
No

Groups and cohorts

  • Cardiometabolic risk group

    Other: No intervention

Interventions

  • OtherNo intervention

    No intervention was involved in this study

06

What researchers measure

Primary outcomes

  1. Visceral fat area cutoffs and cardiometabolic risk

    Based on dual-energy X-ray measurements of visceral fat area, age- and sex-specific visceral fat area cutoffs for screening cardiometabolic risk was developed and validated.

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06554262
Lead sponsor
Capital Medical University
Responsible party
Xia Wang (Principal Investigator, Capital Medical University) — Principal investigator
First posted
Aug 15, 2024
Start date
Jan 2013
Primary completion
Nov 2015
Completion
Sep 2019
Last update
Aug 15, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion